Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ana Huerta Alardin

Gastroenterology Greeley, CO Medical Doctor

NPI 1215198817 CMS profile 145357

8225 W 20Th St, Greeley, CO 80634

Open in the dashboard

General payments

$6,411

287 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ana Huerta Alardin of Greeley, CO is reported in the CMS Open Payments database as having received $6,411 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,163 86
2024 General $2,127 93
2023 General $961 49
2022 General $257 14
2021 General $134 6
2020 General $293 12
2019 General $477 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ana Huerta Alardin
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ana Huerta Alardin were reported at $2,163. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ana Huerta Alardin Gastroenterology median Middle half National median
2019 $477 $417 $126–$1,100 $163
2020 $293 $224 $74–$624 $114
2021 $134 $352 $106–$1,054 $132
2022 $257 $448 $129–$1,270 $149
2023 $961 $533 $150–$1,390 $160
2024 $2,127 $605 $160–$1,606 $164
2025 $2,163 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,406 71 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $999 39 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $632 30 payments
  4. Janssen Biotech, Inc. $591 27 payments
  5. Regeneron Healthcare Solutions, Inc. $469 17 payments
  6. Gilead Sciences, Inc. $276 13 payments
  7. Janssen Scientific Affairs, LLC $243 2 payments
  8. Genzyme Corporation $235 9 payments
  9. Pfizer Inc. $211 11 payments
  10. Ardelyx, Inc. $188 6 payments
  11. Other $1,160 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,300 284 payments
  2. Education $110 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $755 43 payments
  2. ENTYVIO $746 29 payments
  3. XIFAXAN $632 30 payments
  4. TREMFYA $545 16 payments
  5. SKYRIZI Immunology $407 18 payments
  6. SKYRIZI Immunology $341 19 payments
  7. STELARA $290 13 payments
  8. DUPIXENT Inflammation And Immunology $267 11 payments
  9. DUPIXENT Immunology $235 9 payments
  10. DUPIXENT Immunology And Inflammation $202 6 payments
  11. Other $2,546 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,253

Median for Gastroenterology: 569

Drug cost

$128,368

Median for Gastroenterology: $104,976

Branded share of claims

55.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 56 $69,948
Mesalamine Generic 15 $20,401
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 180 $12,268
Omeprazole Generic 383 $7,190
Dexlansoprazole Dr Dexlansoprazole Brand 16 $5,160
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 256 $4,103
Colestipol Hcl Generic 19 $3,160
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 58 $1,492
Sucralfate Generic 13 $1,315
Azathioprine Generic 14 $1,201

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$90,850

Medicare's payments for the services billed

Medicare patients

439

Average age 73

Services billed

1,124

289 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 50%
Diabetes 29%
Depression 26%
Chronic kidney disease 25%
Ischemic heart disease 24%
COPD 16%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $185
  • GENZYME CORPORATION $79
$265 — —
SKYRIZI
  • AbbVie, Inc. $227
$227 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $218
$218 — —
RINVOQ
  • AbbVie, Inc. $182
$182 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $171
$171 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record